Statins attenuate helicobacter pylori CagA translocation and reduce incidence of gastric cancer

In Vitro and population-based case-control studies

Chun Jung Lin, Wei Chih Liao, Hwai Jeng Lin, Yuan Man Hsu, Cheng Li Lin, Yu An Chen, Chun Lung Feng, Chih Jung Chen, Min Chuan Kao, Chih Ho Lai, Chia Hung Kao

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Gastric cancer is the second leading cause of cancer-related death worldwide. The correlation of Helicobacter pylori and the etiology of gastric cancer was substantially certain. Cholesterol-rich microdomains (also called lipid rafts), which provide platforms for signaling, are associated with H. pylori-induced pathogenesis leading to gastric cancer. Patients who have been prescribed statins, inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase, have exhibited a reduced risk of several types of cancer. However, no studies have addressed the effect of statins on H. pylori-associated gastric cancer from the antineoplastic perspective. In this study, we showed that treatment of gastric epithelial cells with simvastatin reduced the level of cellular cholesterol and led to attenuation of translocation and phosphorylation of H. pylori cytotoxin-associated gene A (CagA), which is recognized as a major determinant of gastric cancer development. Additionally, a nationwide case-control study based on data from the Taiwanese National Health Insurance Research Database (NHIRD) was conducted. A population-based case-control study revealed that patients who used simvastatin exhibited a significantly reduced risk of gastric cancer (adjusted odds ratio (OR) = 0.76, 95% confidence interval (CI) = 0.70-0.83). In patients exhibiting H. pylori infection who were prescribed simvastatin, the adjusted OR for gastric cancer was 0.25 (95% CI = 0.12-0.50). Our results combined an in vitro study with a nationwide population analysis reveal that statin use might be a feasible approach to prevent H. pylori-associated gastric cancer.

Original languageEnglish
Article numbere0146432
JournalPLoS One
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 5 2016

Fingerprint

cytotoxins
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Simvastatin
stomach neoplasms
Helicobacter pylori
Cytotoxins
case-control studies
Stomach Neoplasms
Case-Control Studies
Genes
incidence
Incidence
Cholesterol
Health insurance
Population
Phosphorylation
genes
Antineoplastic Agents
Oxidoreductases
odds ratio

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Statins attenuate helicobacter pylori CagA translocation and reduce incidence of gastric cancer : In Vitro and population-based case-control studies. / Lin, Chun Jung; Liao, Wei Chih; Lin, Hwai Jeng; Hsu, Yuan Man; Lin, Cheng Li; Chen, Yu An; Feng, Chun Lung; Chen, Chih Jung; Kao, Min Chuan; Lai, Chih Ho; Kao, Chia Hung.

In: PLoS One, Vol. 11, No. 1, e0146432, 05.01.2016.

Research output: Contribution to journalArticle

Lin, Chun Jung ; Liao, Wei Chih ; Lin, Hwai Jeng ; Hsu, Yuan Man ; Lin, Cheng Li ; Chen, Yu An ; Feng, Chun Lung ; Chen, Chih Jung ; Kao, Min Chuan ; Lai, Chih Ho ; Kao, Chia Hung. / Statins attenuate helicobacter pylori CagA translocation and reduce incidence of gastric cancer : In Vitro and population-based case-control studies. In: PLoS One. 2016 ; Vol. 11, No. 1.
@article{dae40de6722f406fbcaf3afd8a617f86,
title = "Statins attenuate helicobacter pylori CagA translocation and reduce incidence of gastric cancer: In Vitro and population-based case-control studies",
abstract = "Gastric cancer is the second leading cause of cancer-related death worldwide. The correlation of Helicobacter pylori and the etiology of gastric cancer was substantially certain. Cholesterol-rich microdomains (also called lipid rafts), which provide platforms for signaling, are associated with H. pylori-induced pathogenesis leading to gastric cancer. Patients who have been prescribed statins, inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase, have exhibited a reduced risk of several types of cancer. However, no studies have addressed the effect of statins on H. pylori-associated gastric cancer from the antineoplastic perspective. In this study, we showed that treatment of gastric epithelial cells with simvastatin reduced the level of cellular cholesterol and led to attenuation of translocation and phosphorylation of H. pylori cytotoxin-associated gene A (CagA), which is recognized as a major determinant of gastric cancer development. Additionally, a nationwide case-control study based on data from the Taiwanese National Health Insurance Research Database (NHIRD) was conducted. A population-based case-control study revealed that patients who used simvastatin exhibited a significantly reduced risk of gastric cancer (adjusted odds ratio (OR) = 0.76, 95{\%} confidence interval (CI) = 0.70-0.83). In patients exhibiting H. pylori infection who were prescribed simvastatin, the adjusted OR for gastric cancer was 0.25 (95{\%} CI = 0.12-0.50). Our results combined an in vitro study with a nationwide population analysis reveal that statin use might be a feasible approach to prevent H. pylori-associated gastric cancer.",
author = "Lin, {Chun Jung} and Liao, {Wei Chih} and Lin, {Hwai Jeng} and Hsu, {Yuan Man} and Lin, {Cheng Li} and Chen, {Yu An} and Feng, {Chun Lung} and Chen, {Chih Jung} and Kao, {Min Chuan} and Lai, {Chih Ho} and Kao, {Chia Hung}",
year = "2016",
month = "1",
day = "5",
doi = "10.1371/journal.pone.0146432",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Statins attenuate helicobacter pylori CagA translocation and reduce incidence of gastric cancer

T2 - In Vitro and population-based case-control studies

AU - Lin, Chun Jung

AU - Liao, Wei Chih

AU - Lin, Hwai Jeng

AU - Hsu, Yuan Man

AU - Lin, Cheng Li

AU - Chen, Yu An

AU - Feng, Chun Lung

AU - Chen, Chih Jung

AU - Kao, Min Chuan

AU - Lai, Chih Ho

AU - Kao, Chia Hung

PY - 2016/1/5

Y1 - 2016/1/5

N2 - Gastric cancer is the second leading cause of cancer-related death worldwide. The correlation of Helicobacter pylori and the etiology of gastric cancer was substantially certain. Cholesterol-rich microdomains (also called lipid rafts), which provide platforms for signaling, are associated with H. pylori-induced pathogenesis leading to gastric cancer. Patients who have been prescribed statins, inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase, have exhibited a reduced risk of several types of cancer. However, no studies have addressed the effect of statins on H. pylori-associated gastric cancer from the antineoplastic perspective. In this study, we showed that treatment of gastric epithelial cells with simvastatin reduced the level of cellular cholesterol and led to attenuation of translocation and phosphorylation of H. pylori cytotoxin-associated gene A (CagA), which is recognized as a major determinant of gastric cancer development. Additionally, a nationwide case-control study based on data from the Taiwanese National Health Insurance Research Database (NHIRD) was conducted. A population-based case-control study revealed that patients who used simvastatin exhibited a significantly reduced risk of gastric cancer (adjusted odds ratio (OR) = 0.76, 95% confidence interval (CI) = 0.70-0.83). In patients exhibiting H. pylori infection who were prescribed simvastatin, the adjusted OR for gastric cancer was 0.25 (95% CI = 0.12-0.50). Our results combined an in vitro study with a nationwide population analysis reveal that statin use might be a feasible approach to prevent H. pylori-associated gastric cancer.

AB - Gastric cancer is the second leading cause of cancer-related death worldwide. The correlation of Helicobacter pylori and the etiology of gastric cancer was substantially certain. Cholesterol-rich microdomains (also called lipid rafts), which provide platforms for signaling, are associated with H. pylori-induced pathogenesis leading to gastric cancer. Patients who have been prescribed statins, inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase, have exhibited a reduced risk of several types of cancer. However, no studies have addressed the effect of statins on H. pylori-associated gastric cancer from the antineoplastic perspective. In this study, we showed that treatment of gastric epithelial cells with simvastatin reduced the level of cellular cholesterol and led to attenuation of translocation and phosphorylation of H. pylori cytotoxin-associated gene A (CagA), which is recognized as a major determinant of gastric cancer development. Additionally, a nationwide case-control study based on data from the Taiwanese National Health Insurance Research Database (NHIRD) was conducted. A population-based case-control study revealed that patients who used simvastatin exhibited a significantly reduced risk of gastric cancer (adjusted odds ratio (OR) = 0.76, 95% confidence interval (CI) = 0.70-0.83). In patients exhibiting H. pylori infection who were prescribed simvastatin, the adjusted OR for gastric cancer was 0.25 (95% CI = 0.12-0.50). Our results combined an in vitro study with a nationwide population analysis reveal that statin use might be a feasible approach to prevent H. pylori-associated gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84954062609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954062609&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0146432

DO - 10.1371/journal.pone.0146432

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e0146432

ER -